Annual Report

SUPRIYA LIFESCIENCE LTD. " Creati11g true values that bind global l,ealtl, September 1, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir (s), Sub: Notice of the 18th Annual General Meeting, Annual Report FY 2025-26 and the Business Responsibility and Sustainability Report. Further to our Letter dated August 26, 2026, convening that the 18th Annual General Meeting ("AGM") of the Members of the Company is scheduled to be held on Thursday, September 24, 2026, at 03:00 p.m. (IST) through Video Conferencing/ Other Audio Visual Means in accordance with relevant circulars issued by the Ministry of Corporate Affairs and SEBI. Pursuant to Regulation 34(1) and Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial year 2025-26 including the Business Responsibility and Sustainability Report, along with the Notice of AGM, which are being sent through electronic mode to the Members of the Company, whose email IDs are registered with Depositories/ Company/ Registrar and Share Transfer Agent. The Annual Report along with the Notice of the AGM for the Financial Year 2025-26 is also available on the website of the Company at www.supriyalifescience.com under “Investor Section”. The Notice of AGM of the Company inter alia indicates the process and manner of remote e-voting/ e- voting at the AGM and instructions for participating at the AGM through VC/OAVM. Kindly take the said information on your records. Thanking you, Yours faithfully, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE Shaping a Stronger Tomorrow Annual Report 2025-26 Index Shaping a Stronger Tomorrow 01 50 133 For Supriya Lifescience, a Corporate Statutory Financial Overview Section Section stronger future is being shaped Supriya Lifescience at a Glance by the capabilities it builds 50 Notice 133 Financial Statements 01 Shaping a Stronger Tomorrow 63 Management Discussion and today. Leveraging nearly four 04 Trusted Partner in Global Analysis Report decades of pharmaceutical Regulated Lifesciences Space 70 Boards’ Report 08 Milestones in Our Journey 86 Report on Corporate expertise, the Company 10 Extensive Global Footprint Governance is strengthening its core, 12 Supporting Healthcare Across 102 Business Responsibility and Diverse Therapies Sustainability Report expanding into higher-value 16 Delivering Consistent Growth opportunities, and investing in Strategic and Disclaimer Performance Review In this annual report, we have disclosed forward-looking information to enable capabilities that will power its investors to comprehend our prospects and take informed investment decisions. 20 Chairman and Executive next phase of growth. This report and other statements - written and oral - that we periodically make, Director’s Communique contain forward-looking statements that set out anticipated results based on 24 Managing Director’s Message the management’s plans and assumptions. We have tried wherever possible 26 Joint Managing Director’s Message to identify such statements by using words such as ‘anticipates’, ‘estimates’, FY 2025–26 reflected this momentum, with the Company ‘expects’, ‘projects’, ‘intends’, ‘plans’, ‘believes’ and words of similar substance in 28 Driving Growth Through delivering its highest-ever revenue and EBITDA, supported connection with any discussion of future performance. We cannot guarantee that Manufacturing Excellence by strong demand across core therapeutic segments, a these forward-looking statements will be realized, although we believe we have 30 Advancing R&D and favourable product mix, deeper backward integration, and been prudent in our assumptions. The achievement of results is subject to risks, Innovation Capabilities disciplined execution. uncertainties and even inaccurate assumptions. Should known or unknown risks 33 Building a Resilient Supply or uncertainties materialize, or should underlying assumptions prove inaccurate, Supriya continues to reinforce its API franchise through Chain Network actual results could vary materially from those anticipated, estimated or projected. new product development, lifecycle management, and 34 Embedding Quality Across the Readers should kindly bear this in mind. We undertake no obligation to publicly process optimisation, while expanding into new growth Value Chain update any forward-looking statements, whether as a result of new information, avenues. Its enhanced R&D capabilities are enabling the 37 Accelerating Digital future events or otherwise. development of niche molecules, opening CMO/CDMO Transformation opportunities with global pharmaceutical and innovator 38 Deepening Market Reach and companies, and building a differentiated formulations Customer Engagement pipeline. Strategic capacity additions and advanced technologies are strengthening the Company’s capabilities ESG Overview in finished formulations and specialised dosage forms, while the planned development at Patalganga provides headroom 42 Committed to Sustainable Impact m for accelerated expansion. 43 Strengthening Environmental Stewardship With enhanced manufacturing capacity, deeper backward 44 Empowering People integration, world-class R&D, and an unwavering and Communities commitment to quality and regulatory excellence, Supriya is 45 C orporate Social transforming into an integrated, future-ready life sciences See the report online at Responsibility (CSR) organisation, poised to capitalise on unprecedented www.supriyalifescience.com opportunities and deliver sustainable growth. 47 Board of Directors 48 Industry Recognition for Excellence 49 Corporate Information Supriya LIFESCIENCE at a Glance 01 Shaping a Stronger Tomorrow 04 Trusted Partner in Global Regulated Lifesciences Space 08 Milestones in Our Journey 10 Extensive Global Footprint 12 Supporting Healthcare Across Diverse Therapies 16 Delivering Consistent Growth Supriya Lifescience Ltd. Annual Report 2025-26 SR FS Corporate Overview CO Corporate Overview Trusted Partner in Global Regulated Lifesciences Space Values Product Portfolio Established in 1987 as a partnership firm and incorporated as a public limited Sustainability and consistency company in 2008, Supriya Lifescience is a leading global life sciences company Fulfilling all stakeholders’ expectations by engaged in the development and manufacturing of niche Active Pharmaceutical adhering to sustainable, consistent and ethical The Company offers a robust business practices portfolio of 40+ specialised APIs, Ingredients (APIs), formulations, and CMO/CDMO solutions. Headquartered with 15 backward-integrated in Mumbai, the Company serves over 1,500 customers across 120+ countries, Integrity and Sincerity products, spanning key therapeutic segments including anaesthetics, reinforcing its position as a trusted global pharmaceutical partner. Retain the trust of customers by consistently antihistamines, analgesics, meeting their quality and delivery vitamins, anti-asthmatics, and Backed by state-of-the-art manufacturing facilities, deep chemistry expertise, and advanced R&D timeline expectations anti-allergics, among others, capabilities, the Company delivers high-quality solutions [Showing first 8,000 characters — download PDF for full document]